• The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 

      Flatø, Berit; Rygg, Marite; Nordal, Ellen Berit; Røisland, Mona; Ødegård, Hanne Beate; Hoftun, Gry Børmark; Songstad, Nils Thomas; Consolaro, Alessandro; Bovis, Francesca; Ruperto, Nicolino (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-04-07)
      The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Norwegian language. The reading comprehension of ...
    • Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 

      van Straalen, Joeri W.; de Roock, Sytze; Giancane, Gabriella; Consolaro, Alessandro; Rygg, Marite; Nordal, Ellen Berit; Rubio-Pérez, Nadina; Jelusic, Marija; De Inocencio, Jaime; Vojinovic, Jelena; Wulffraat, Nico M.; Bruijning-Verhagen, Patricia C. J.; Ruperto, Nicolino; Swart, Joost F. (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-14)
      Background: Etanercept (ETN) and adalimumab (ADA) are considered equally efective biologicals in the treat‑ ment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a diferential efect on patientreported well-being in non-systemic JIA using real-world ...